Antigen study supports new approach to vaccine for respiratory syncytial virus

March 9, 2018, University of California - Santa Cruz
Immune system antibodies can block RSV infection and provide protection from RSV disease. This image shows how a protective human antibody (dark and light grey surface) sticks to a folded part of the RSV G protein antigen (rainbow colored blue-to-red). The new findings provide a foundation for the development of a RSV vaccine. Credit: Rebecca DuBois

Medical researchers have been trying to develop a vaccine for respiratory syncytial virus (RSV) for more than 50 years, without success. New findings by researchers at UC Santa Cruz, however, point to a promising route for designing an effective vaccine.

For most people, an RSV infection is just a bad cold, but for infants and older adults it can cause serious pneumonia or bronchial inflammation. In the 1960s, a traditional based on inactivated was found to actually make the disease worse. More recently, of two different vaccines based on one of the viral surface proteins (the RSV F ) have also failed.

The new study, published March 9 in Science Immunology, focused on the other major viral surface protein, the RSV G glycoprotein. Leveraging work by collaborators at Trellis Bioscience who have isolated protective human targeting the G glycoprotein, the UCSC researchers determined the atomic structure of RSV G and identified two sites on it that are targeted by protective antibodies effective against a broad range of RSV strains.

Corresponding author Rebecca DuBois, assistant professor of biomolecular engineering at UC Santa Cruz, said RSV G had been overlooked by vaccine researchers because initial studies found that deleting the gene for it didn't stop the virus from replicating in cell cultures. Studies in animal models, however, showed that virus lacking the G glycoprotein is significantly weakened.

Crystal structures of protein complexes formed between RSV G antigen (cyan) and broadly neutralizing monoclonal antibody 3D3 (light and dark grey). Credit: Fedechkin et al., Sci. Immunol. 3, eaar3534 (2018)

"The G glycoprotein is actually very important," DuBois said. "It's the attachment protein that allows the virus to stick to lung cells, while the F glycoprotein promotes entry into the cell. Once the virus infects a cell and starts replicating, it makes a secreted form of the G glycoprotein that goes out and starts flipping switches on our immune cells, distorting our immune responses."

This disruption of the immune response by RSV G may explain why vaccines based on RSV F have failed, she said. "You need a protective antibody response that blocks that RSV G activity, but we didn't know how antibodies target RSV G at the molecular level."

In the new study, DuBois showed that these protective antibodies target a section of the protein called the central conserved domain that is the same in all strains of the virus. The researchers determined the three-dimensional atomic structures of the precise binding sites of two Trellis antibodies—crucial information for designing a vaccine that can induce the immune system to produce such protective antibodies.

Video interview (with music overlay) with corresponding author Rebecca Dubois, who talks about the inspiration behind her research of a respiratory syncytial virus vaccine and the implications of her findings. Credit: Credit: Andrew Jones / UC Santa Cruz

"We're really excited about the possibility of finally being able to conquer this virus, which is one of the most important childhood viruses for which we don't have a vaccine," DuBois said.

In developing a vaccine based on RSV G, however, researchers would have to ensure that the vaccine lacks the viral protein's ability to disrupt the immune system. "There has been a lot of concern about making a vaccine with the G glycoprotein. We need to engineer it so that it can't subvert the immune system, while keeping its ability to elicit an effective antibody response," DuBois said.

Trellis Bioscience, meanwhile, is investigating the therapeutic use of the antibodies themselves to treat infants with RSV infection and severe lung congestion, with clinical trials expected to start in early 2019. If proven effective, the demand for a vaccine that elicits protective antibodies targeting the G glycoprotein will intensify, particularly for global use, DuBois said.

Explore further: Why the latest shingles vaccine is more than 90 percent effective

More information: S.O. Fedechkin el al., "Structures of respiratory syncytial virus G antigen bound to broadly neutralizing antibodies," Science Immunology (2018). … 6/sciimmunol.aar3534

Related Stories

Why the latest shingles vaccine is more than 90 percent effective

March 7, 2018
A new study has shown how the body's immune system responds to the new shingles vaccine, Shingrix, making it more than 90% effective at protecting against the virus.

Scientists gain new insight on how antibodies interact with widespread respiratory virus

February 22, 2018
Scientists have found and characterized the activity of four antibodies produced by the human immune system that target an important protein found in respiratory syncytial virus (RSV), according to new research published ...

Past encounters with the flu shape vaccine response

February 20, 2018
New research on why the influenza vaccine was only modestly effective in recent years shows that immune history with the flu influences a person's response to the vaccine.

Researchers develop new method to 'fingerprint' HIV

March 28, 2017
HIV is a master of disguise. The virus uses a shield of sugar molecules, called glycans, to hide from the immune system and block antibodies from attacking it.

Structure of human astrovirus could lead to antiviral therapies, vaccines

November 21, 2016
Human astroviruses infect nearly everyone during childhood, causing diarrhea, vomiting, and fever. For most people, it's not a serious disease, but structural biologist Rebecca DuBois saw how devastating it can be when she ...

New molecule shows promise in HIV vaccine design

October 27, 2017
Researchers at the University of Maryland and Duke University have designed a novel protein-sugar vaccine candidate that, in an animal model, stimulated an immune response against sugars that form a protective shield around ...

Recommended for you

Bystander T cells can steal the show in resolving inflammation

March 23, 2018
In Type 1 diabetes the immune system mistakenly attacks and destroys insulin-producing pancreatic cells, leaving patients dependent on lifelong insulin injections. The putative perpetrators of the attack—which are called ...

Researchers discover a 'security chief' that sounds the alarm against infections

March 23, 2018
St. Jude Children's Research Hospital scientists have identified a key molecule that serves as a "security chief" to help the immune system quickly recognize and fight infections with dangerous gram-negative bacteria like ...

Whether the donor and recipient are male or female influences transplant rejection rates—investigators explore why

March 22, 2018
Biological sex differences can have far-reaching, clinical consequences, as illustrated by organ transplant outcomes. Men and women who receive donated organs can have different rates of transplant rejection, in some cases ...

Mumps resurgence likely due to waning vaccine-derived immunity

March 21, 2018
A resurgence of mumps in the U.S. among vaccinated young adults appears to be due to waning of vaccine-induced immunity, according to a new analysis from Harvard T.H. Chan School of Public Health. Researchers found that vaccine-derived ...

How allergens trigger asthma attacks

March 19, 2018
A team of Inserm and CNRS researchers from the Institute of Pharmacology and Structural Biology have identified a protein that acts like a sensor detecting allergens in the respiratory tract that are responsible for asthma ...

Single steroid-bronchodilator treatment for control and rescue improves persistent asthma

March 19, 2018
When it comes to treating teens and adults with persistent asthma, using a single corticosteroid and long-acting bronchodilator treatment for both daily asthma control and for rescue relief during sudden asthma attacks is ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.